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communication). Is a combination of an active azole 
with liposomal amphotericin B or an echinocandin a 
more potent treatment than the current treatment 
with either liposomal amphotericin B or an active azole? 
Some in-vitro indications suggest that it might be.12 
Clinical studies of such rare diseases are very diﬃ  cult or 
even impossible to do. Alternatively, large well designed 
and functioning global registries such as FungiScope 
or Zygomyconet might be helpful for providing data 
on management of these rare diseases. Bringing active 
and safe treatments for rare fungal diseases, such 
as mucormycosis, to clinical practice is diﬃ  cult, but 
the present report deﬁ nitely opened a new path to 
achievement of this goal.
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Improving helminth treatment access: costs and opportunities
Soil-transmitted helminths aﬀ ect about 1·5 billion 
people living in the world’s poorest regions.1 The main 
public health strategy for morbidity control is mass drug 
administration (MDA; also referred to as preventive 
chemotherapy), which is the widespread empirical 
treatment of populations, traditionally school-aged 
children.2 WHO set a goal of achieving 75% coverage of 
at-risk populations by 2020, but estimates from 2014 
suggest only 47% global coverage of children.3 To reach 
the WHO 2020 goal, opportunities must be taken to ﬁ nd 
cost eﬃ  ciencies, collaborate across health sectors, and 
improve measurement of the costs and eﬀ ects of MDA 
programmes. The substantial gap in target coverage for 
treatment of soil-transmitted helminths poses a great 
challenge, but an even greater opportunity to address 
the global burden from these infections. 
In The Lancet Infectious Diseases, Hugo Turner and col-
leagues4 present a much needed and pragmatic analysis 
to address knowledge gaps in the cost of school-based 
MDA against soil-transmitted helminths. In their analysis, 
they used 3 years of programmatic cost data from six 
Ugandan districts, and found a relation between higher 
coverage and lower per-treatment delivery cost (known as 
economies of scale). Their primary ﬁ nding that economies 
of scale apply to MDA, although suspected, had yet to 
be fully assessed for soil-transmitted helminths. The 
investigators showed the implications of this ﬁ nding by 
using a case study to examine the cost-eﬀ ectiveness of 
school-based MDA targeting Ascaris lumbricoides. They 
found that cost-eﬀ ectiveness increased with greater 
treatment coverage when economies of scale were 
considered, by contrast with projections using a constant 
cost per treatment, irrespective of coverage, in which 
cost-eﬀ ectiveness decreased with scale. For example, 
when control was scaled up from 10% to 75% coverage of 
at-risk school-age children, the cost-eﬀ ectiveness in terms 
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of prevention of heavy burden infections was projected 
to increase when using the cost function, but to decrease 
when assuming a constant cost per treatment. The 
investigators suggest that past assumptions of constant 
costs can therefore be misleading in select cases. The 
implication of this ﬁ nding is that past cost-eﬀ ectiveness 
estimates were conservative, since no cost advantages 
were assumed with higher coverage. Indeed, these 
school-based programmes are likely to be even more cost-
eﬀ ective than previously believed when reaching high 
MDA coverage. 
As treatment for soil-transmitted helminths is scaled 
up across countries, substantial opportunities exist to 
further maximise cost eﬃ  ciencies through co-delivery 
of soil-transmitted helminth treatment programmes 
with other MDAs and general health programming. Such 
opportunities for an integrated platform that combines 
soil-transmitted helminth treatment with other health 
programmes exist across a range of interventions, 
including other MDAs for neglected tropical diseases 
(eg, schistosomiasis, lymphatic ﬁ lariasis, onchocerciasis, 
and trachoma);5,6 infectious diseases (eg, HIV, tuber-
culosis, and malaria);7 improvements in water, sani-
tation, and hygiene programming;8 general public health 
programmes (eg, vaccination campaigns and vitamin 
A supplementation campaigns);9 and even household 
surveys (eg, demographic and health surveys via the DHS 
Program). Integrated programming is likely to result in 
cost savings, biological synergies in which several health 
interventions boost each other’s eﬀ ect, and a unique 
opportunity to break down traditional disease silos and 
collaborate across sectors to improve health care.5–7,9,10 
For cost-eﬀ ectiveness studies, further investigation 
is needed to improve understanding of disability from 
helminth infections and formalise a consensus on more 
conventional outcome measures, including the disability-
adjusted life-year.11 This metric enables economic com-
parisons across many diﬀ erent health interventions to 
inform health-care spending,11 and can include all health 
beneﬁ ts accrued with individual treatment (eg, albendazole 
treats many helminths, including A lumbricoides, 
hookworm, and Trichuris trichiura). Turner and colleagues4 
reported eﬀ ectiveness outcomes of worm-years averted, 
prevalent infection case-years averted, and heavy infection 
case-years averted. The challenge with some of these 
outcome measures is the important non-linear relations 
between prevalence, worm burden (ie, infection intensity), 
and disability, and also limited knowledge about the 
eﬀ ect of minor diﬀ erences in number of worms on an 
individual’s disability. The investigators presumably chose 
these outcomes—as opposed to disability-adjusted life-
years—because of controversy regarding use of a disability 
weight that adequately captures all disease morbidity. 
Nevertheless, to accurately make economic comparisons 
among MDA and other competing health priorities, 
collaborative development of a consensus regarding 
disability weights and collection of additional data if there 
is substantial uncertainty will be important.
The investigators also highlight remaining data 
limitations that can guide future research on pro-
grammatic treatment of helminths. Although their 
analysis focused on school-based programming, evidence 
and global support is increasing for expansion of treat ment 
from only school-aged children to entire communities to 
approach disease elimination and avert the substantial 
morbidity in both children and adults, even if elimination 
is not reached.6,12 As the investigators discuss, future 
studies should examine the relation between coverage 
and cost of community-wide treatment and the increased 
cost of reaching repeatedly untreated populations (ie, 
hard-to-reach populations). Furthermore, the study 
ﬁ ndings of a lower per-person treatment cost associated 
with higher coverage suggests that populations are likely 
to be able to receive treatment at a lower prevalence 
than recommended currently.2 This ﬁ nding suggests the 
importance of re-examining current MDA guidelines 
for helminth infections, and potentially lowering the 
prevalence thresholds for MDA in these settings.6
Since individual countries determine health priorities, 
treatment of helminth infections—especially when 
integrated with other health programming—provides 
an attractive and cost-eﬀ ective option. To reach the 
WHO 2020 goal for 75% coverage, there are great 
opportunities to integrate soil-transmitted helminth 
treatment with other health programming, use research 
to guide programmatic treatment delivery, and improve 
the measurement of the eﬀ ect of MDA. If we ignore 
these opportunities, then we will have to consider the 
cost of failing to do our best to reach the populations 
who bear the burden of helminth infections.
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Next steps for antimicrobial stewardship 
The rising tide of antimicrobial resistance, coupled with a 
paucity of new drug development, have led to increasingly 
clamorous calls for improved antimicrobial stewardship 
to reduce the oft-cited 30–50% rate of inappropriate 
antimicrobial therapy.1–5 Much attention has been given 
to what approaches stewardship pro grammes should 
include to achieve speciﬁ c objectives, such as adherence 
to local guidelines, use of pathogen-directed therapy, 
discontinuation of therapy when infec tion is found to 
be unlikely, timely switching from parenteral to oral 
treatment, and appropriate duration of therapy. However, 
a substantial degree of uncertainty remains about which 
speciﬁ c strategies will best achieve these objectives (eg, 
drug restrictions, audit and feedback, computerised 
decision support systems), how to assure successful 
implementation, and whether interventions sustainably 
reduce antimicrobial use and lead to meaningful 
improvements in outcomes at the patient level (eg, 
adverse events, mortality) and societal level (costs and 
bacterial resistance).6,7
In The Lancet Infectious Diseases, Emelie C Schuts and 
colleagues,8 instead of taking the usual approach of 
focusing on the strategies aimed at achieving stewardship 
objectives, focus instead on the eﬀ ect of meeting these 
objectives. The authors identiﬁ ed 14 relevant objectives 
compiled via expert Delphi procedures and from 
guidelines, and exhaustively reviewed the literature to 
ﬁ nd studies that had assessed the eﬀ ects of meeting each 
one on patient-level and society-level outcomes (clinical 
outcomes, adverse events, costs, and bacterial resistance 
rates). Data were available on nine of the 14 objectives in 
145 unique studies. Signiﬁ cant beneﬁ ts were seen for at 
least one outcome for the following outcomes: empirical 
therapy according to guidelines, de-escalation of therapy, 
switch from intravenous to oral treatment, therapeutic 
drug monitoring, use of a list of restricted antibiotics, 
and bedside consultation. For mortality, signiﬁ cant 
eﬀ ects were seen with adherence to guidelines (relative 
risk reduction 35%; relative risk 0·65, 95% CI 0·54–0·80, 
p<0·0001) and de-escalation of therapy (66%; 0·44, 
0·30–0·66, p<0·0001). 
Schuts and colleagues have assembled a com-
prehensive and well organised compendium that 
identiﬁ es the gaps in data linking stewardship objectives 
to practical outcomes. Unfortunately, almost all 
studies were of poor quality owing to inconsistency, 
indirectness, and imprecision in data reporting, and 
overall risk of bias was high. Nevertheless, the eﬀ ect on 
mortality achieved with de-escalation of therapy, which 
was based on culture results derived from 25 studies in 
diverse clinical settings, is provocative. The decrease 
in mortality associated with guideline-concordant 
Published Online
March 2, 2016
http://dx.doi.org/10.1016/
S1473-3099(16)00099-2
See Articles page 847
Ch
ris
 G
al
la
gh
er
/S
cie
nc
e 
Ph
ot
o 
Li
br
ar
y 
